Pembrolizumab (pembro) in Patients (pts) with Sorafenib-Treated (cohort 1) and Treatment (Tx)-Naive (cohort 2) Advanced Hepatocellular Carcinoma (ahcc) after Additional Follow-Up in the Phase 2 KEYNOTE-224 Study.